Literature DB >> 23562472

The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.

Hui Ren1, Liqun Zhao, Yikun Li, Ping Yue, Xingming Deng, Taofeek K Owonikoko, Mingwei Chen, Fadlo R Khuri, Shi-Yong Sun.   

Abstract

This study focuses on determining whether and how the novel PI3 kinase inhibitor NVP-BKM120 (BKM120) induces apoptosis and enhances TRAIL-induced apoptosis in human lung cancer cells. We found that BKM120 reduced Mcl-1 levels across the tested cell lines along with induction of apoptosis and enhancement of TRAIL-induced apoptosis. Enforced expression of ectopic Mcl-1 significantly attenuated the effects of BKM120 alone or in combination with TRAIL on induction of apoptosis. Thus Mcl-1 downregulation contributes to BKM120-induced apoptosis or enhancement of TRAIL-induced apoptosis. Moreover, we have demonstrated that BMK120 decreases Mcl-1 levels through facilitating its degradation involving a GSK3/FBXW7-dependent mechanism.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; BKM120; Lung cancer; PI3 kinase; TRAIL

Mesh:

Substances:

Year:  2013        PMID: 23562472      PMCID: PMC3750077          DOI: 10.1016/j.canlet.2013.03.032

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  45 in total

1.  Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Authors:  Guillaume Jacquemin; Virginie Granci; Anne Sophie Gallouet; Najoua Lalaoui; Aymeric Morlé; Elisabetta Iessi; Alexandre Morizot; Carmen Garrido; Thierry Guillaudeux; Olivier Micheau
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.

Authors:  Daniela Opel; Ivonne Naumann; Maxi Schneider; Daniela Bertele; Klaus-Michael Debatin; Simone Fulda
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

Review 3.  TRAIL receptor signaling and therapeutics.

Authors:  Junaid Abdulghani; Wafik S El-Deiry
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

Review 4.  Mcl-1; the molecular regulation of protein function.

Authors:  Luke W Thomas; Connie Lam; Steven W Edwards
Journal:  FEBS Lett       Date:  2010-06-11       Impact factor: 4.124

5.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.

Authors:  Ingrid E Wertz; Saritha Kusam; Cynthia Lam; Toru Okamoto; Wendy Sandoval; Daniel J Anderson; Elizabeth Helgason; James A Ernst; Mike Eby; Jinfeng Liu; Lisa D Belmont; Josh S Kaminker; Karen M O'Rourke; Kanan Pujara; Pawan Bir Kohli; Adam R Johnson; Mark L Chiu; Jennie R Lill; Peter K Jackson; Wayne J Fairbrother; Somasekar Seshagiri; Mary J C Ludlam; Kevin G Leong; Erin C Dueber; Heather Maecker; David C S Huang; Vishva M Dixit
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

6.  A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.

Authors:  Tugba Bagci-Onder; Hiroaki Wakimoto; Maarten Anderegg; Cody Cameron; Khalid Shah
Journal:  Cancer Res       Date:  2010-11-17       Impact factor: 12.701

7.  TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1.

Authors:  J K Son; S Varadarajan; S B Bratton
Journal:  Cell Death Differ       Date:  2010-02-19       Impact factor: 15.828

Review 8.  TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.

Authors:  Anita C Bellail; Ling Qi; Patrick Mulligan; Vaninder Chhabra; Chunhai Hao
Journal:  Rev Recent Clin Trials       Date:  2009-01

9.  BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.

Authors:  Shengbing Huang; Kenji Okumura; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

10.  SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.

Authors:  Hiroyuki Inuzuka; Shavali Shaik; Ichiro Onoyama; Daming Gao; Alan Tseng; Richard S Maser; Bo Zhai; Lixin Wan; Alejandro Gutierrez; Alan W Lau; Yonghong Xiao; Amanda L Christie; Jon Aster; Jeffrey Settleman; Steven P Gygi; Andrew L Kung; Thomas Look; Keiichi I Nakayama; Ronald A DePinho; Wenyi Wei
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

View more
  16 in total

1.  Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.

Authors:  Chie Ishikawa; Masachika Senba; Naoki Mori
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

2.  mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.

Authors:  Junghui Koo; Ping Yue; Xingming Deng; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cell Biol       Date:  2015-04-27       Impact factor: 4.272

3.  Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.

Authors:  Shanna K Nifoussi; Nora R Ratcliffe; Deborah L Ornstein; Gary Kasof; Stefan Strack; Ruth W Craig
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

4.  NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.

Authors:  Kimberly A Foster; Esther P Jane; Daniel R Premkumar; Alejandro Morales; Ian F Pollack
Journal:  Int J Oncol       Date:  2015-06-05       Impact factor: 5.650

5.  Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1.

Authors:  Tao Zhang; Shanna Qu; Qi Shi; Dalin He; Xunbo Jin
Journal:  Int J Mol Sci       Date:  2014-02-21       Impact factor: 5.923

6.  Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.

Authors:  Puyu Shi; You-Take Oh; Liang Deng; Guojing Zhang; Guoqing Qian; Shuo Zhang; Hui Ren; Grant Wu; Benjamin Legendre; Emily Anderson; Suresh S Ramalingam; Taofeek K Owonikoko; Mingwei Chen; Shi-Yong Sun
Journal:  Clin Cancer Res       Date:  2017-08-01       Impact factor: 12.531

7.  Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.

Authors:  Zhongqi Ge; Jake S Leighton; Yumeng Wang; Xinxin Peng; Zhongyuan Chen; Hu Chen; Yutong Sun; Fan Yao; Jun Li; Huiwen Zhang; Jianfang Liu; Craig D Shriver; Hai Hu; Helen Piwnica-Worms; Li Ma; Han Liang
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.995

8.  The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis.

Authors:  Hui Ren; Junghui Koo; Baoxiang Guan; Ping Yue; Xingming Deng; Mingwei Chen; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cancer       Date:  2013-11-22       Impact factor: 27.401

9.  Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.

Authors:  Laia Rosich; Arnau Montraveta; Sílvia Xargay-Torrent; Mónica López-Guerra; Jocabed Roldán; Marta Aymerich; Itziar Salaverria; Sílvia Beà; Elías Campo; Patricia Pérez-Galán; Gaël Roué; Dolors Colomer
Journal:  Oncotarget       Date:  2014-08-30

Review 10.  Mechanisms of resistance to EGFR tyrosine kinase inhibitors.

Authors:  Lihua Huang; Liwu Fu
Journal:  Acta Pharm Sin B       Date:  2015-07-26       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.